.webp)
Key takeaways:
- IBS-related costs in the United States exceed $21 billion each year, driven by repeated investigations, pharmacotherapy, and fragmented management that fail to address gut-brain mechanisms.
- The AGA now formally recognizes brain-gut behavior therapies such as gut-directed hypnotherapy as evidence-based components of IBS management, including digital delivery as a scalable, validated alternative.
- In a real-world analysis of more than 4,000 adults, self-reported IBS-related healthcare costs fell from $1,259 before Nerva to $502 at six-month follow-up, a reduction of more than 50%.
- Clinicians who refer through the online form give patients an automatic 25% referral adjustment, and Nerva's Patient Assistance Program can extend coverage up to full access at no cost.
The economic burden of IBS
IBS imposes a significant health-economic burden – not only on patients but across the healthcare system. In the United States, IBS-related costs exceed $21 billion each year, largely due to repeated investigations, pharmacotherapy, and fragmented management that fail to address the gut-brain mechanisms driving symptoms.¹
For patients with persistent or refractory presentations, these cycles contribute to escalating personal and system-level costs without corresponding functional gains.
